164 related articles for article (PubMed ID: 12844462)
1. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitors or calcium channel blocker vs diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Siragy HM
Curr Hypertens Rep; 2003 Aug; 5(4):293-4. PubMed ID: 12844462
[No Abstract] [Full Text] [Related]
2. Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Rahman M; Pressel S; Davis BR; Nwachuku C; Wright JT; Whelton PK; Barzilay J; Batuman V; Eckfeldt JH; Farber M; Henriquez M; Kopyt N; Louis GT; Saklayen M; Stanford C; Walworth C; Ward H; Wiegmann T
Arch Intern Med; 2005 Apr; 165(8):936-46. PubMed ID: 15851647
[TBL] [Abstract][Full Text] [Related]
3. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial
JAMA; 2002 Dec; 288(23):2981-97. PubMed ID: 12479763
[TBL] [Abstract][Full Text] [Related]
4. Role of diuretics in the prevention of heart failure: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.
Davis BR; Piller LB; Cutler JA; Furberg C; Dunn K; Franklin S; Goff D; Leenen F; Mohiuddin S; Papademetriou V; Proschan M; Ellsworth A; Golden J; Colon P; Crow R;
Circulation; 2006 May; 113(18):2201-10. PubMed ID: 16651474
[TBL] [Abstract][Full Text] [Related]
5. Antihypertensive pharmacogenetic effect of fibrinogen-beta variant -455G>A on cardiovascular disease, end-stage renal disease, and mortality: the GenHAT study.
Lynch AI; Boerwinkle E; Davis BR; Ford CE; Eckfeldt JH; Leiendecker-Foster C; Arnett DK
Pharmacogenet Genomics; 2009 Jun; 19(6):415-21. PubMed ID: 19352213
[TBL] [Abstract][Full Text] [Related]
6. Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Barzilay JI; Davis BR; Cutler JA; Pressel SL; Whelton PK; Basile J; Margolis KL; Ong ST; Sadler LS; Summerson J;
Arch Intern Med; 2006 Nov; 166(20):2191-201. PubMed ID: 17101936
[TBL] [Abstract][Full Text] [Related]
7. Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril.
Wright JT; Dunn JK; Cutler JA; Davis BR; Cushman WC; Ford CE; Haywood LJ; Leenen FH; Margolis KL; Papademetriou V; Probstfield JL; Whelton PK; Habib GB;
JAMA; 2005 Apr; 293(13):1595-608. PubMed ID: 15811979
[TBL] [Abstract][Full Text] [Related]
8. Risk of hospitalized gastrointestinal bleeding in persons randomized to diuretic, ACE-inhibitor, or calcium-channel blocker in ALLHAT.
Phillips W; Piller LB; Williamson JD; Whittle J; Jafri SZ; Ford CE; Einhorn PT; Oparil S; Furberg CD; Grimm RH; Alderman MH; Davis BR; Probstfield JL;
J Clin Hypertens (Greenwich); 2013 Nov; 15(11):825-32. PubMed ID: 24283598
[TBL] [Abstract][Full Text] [Related]
9. [ALLHAT trial--antithesis to the overuse of vasodilating antihypertensive drugs].
Kuwajima I
Nihon Rinsho; 2004 Mar; 62 Suppl 3():648-53. PubMed ID: 15171450
[No Abstract] [Full Text] [Related]
10. Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Whelton PK; Barzilay J; Cushman WC; Davis BR; Iiamathi E; Kostis JB; Leenen FH; Louis GT; Margolis KL; Mathis DE; Moloo J; Nwachuku C; Panebianco D; Parish DC; Pressel S; Simmons DL; Thadani U;
Arch Intern Med; 2005 Jun; 165(12):1401-9. PubMed ID: 15983290
[TBL] [Abstract][Full Text] [Related]
11. Blood pressure control and cardiovascular outcomes in normal-weight, overweight, and obese hypertensive patients treated with three different antihypertensives in ALLHAT.
Reisin E; Graves JW; Yamal JM; Barzilay JI; Pressel SL; Einhorn PT; Dart RA; Retta TM; Saklayen MG; Davis BR;
J Hypertens; 2014 Jul; 32(7):1503-13; discussion 1513. PubMed ID: 24842697
[TBL] [Abstract][Full Text] [Related]
12. Mortality and morbidity during and after Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial: results by sex.
Oparil S; Davis BR; Cushman WC; Ford CE; Furberg CD; Habib GB; Haywood LJ; Margolis K; Probstfield JL; Whelton PK; Wright JT;
Hypertension; 2013 May; 61(5):977-86. PubMed ID: 23529173
[TBL] [Abstract][Full Text] [Related]
13. [Old or new antihypertensive drugs? Consequences from ALLHAT. Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial].
Düsing R
Dtsch Med Wochenschr; 2003 Jan; 128(5):214-6. PubMed ID: 12557115
[No Abstract] [Full Text] [Related]
14. Cost-effectiveness of chlorthalidone, amlodipine, and lisinopril as first-step treatment for patients with hypertension: an analysis of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Heidenreich PA; Davis BR; Cutler JA; Furberg CD; Lairson DR; Shlipak MG; Pressel SL; Nwachuku C; Goldman L
J Gen Intern Med; 2008 May; 23(5):509-16. PubMed ID: 18228109
[TBL] [Abstract][Full Text] [Related]
15. Clinical outcomes by race in hypertensive patients with and without the metabolic syndrome: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Wright JT; Harris-Haywood S; Pressel S; Barzilay J; Baimbridge C; Bareis CJ; Basile JN; Black HR; Dart R; Gupta AK; Hamilton BP; Einhorn PT; Haywood LJ; Jafri SZ; Louis GT; Whelton PK; Scott CL; Simmons DL; Stanford C; Davis BR
Arch Intern Med; 2008 Jan; 168(2):207-17. PubMed ID: 18227370
[TBL] [Abstract][Full Text] [Related]
16. The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Heart Failure Validation Study: diagnosis and prognosis.
Einhorn PT; Davis BR; Massie BM; Cushman WC; Piller LB; Simpson LM; Levy D; Nwachuku CE; Black HR;
Am Heart J; 2007 Jan; 153(1):42-53. PubMed ID: 17174636
[TBL] [Abstract][Full Text] [Related]
17. [Are all antihypertensive agents equal? Cardiovascular events in hypertensive patients randomized to treatment with doxazosin or chlorthalidone. The ALLHAT study].
Schillaci G; Verdecchia P
Ital Heart J Suppl; 2000 Sep; 1(9):1215-7. PubMed ID: 11140297
[No Abstract] [Full Text] [Related]
18. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group.
JAMA; 2000 Apr; 283(15):1967-75. PubMed ID: 10789664
[TBL] [Abstract][Full Text] [Related]
19. Blood pressure control by drug group in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Cushman WC; Ford CE; Einhorn PT; Wright JT; Preston RA; Davis BR; Basile JN; Whelton PK; Weiss RJ; Bastien A; Courtney DL; Hamilton BP; Kirchner K; Louis GT; Retta TM; Vidt DG;
J Clin Hypertens (Greenwich); 2008 Oct; 10(10):751-60. PubMed ID: 19090876
[TBL] [Abstract][Full Text] [Related]
20. Baseline characteristics of the diabetic participants in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Barzilay JI; Jones CL; Davis BR; Basile JN; Goff DC; Ciocon JO; Sweeney ME; Randall OS;
Diabetes Care; 2001 Apr; 24(4):654-8. PubMed ID: 11315826
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
